216 related articles for article (PubMed ID: 24739041)
1. SGK3 is an androgen-inducible kinase promoting prostate cancer cell proliferation through activation of p70 S6 kinase and up-regulation of cyclin D1.
Wang Y; Zhou D; Chen S
Mol Endocrinol; 2014 Jun; 28(6):935-48. PubMed ID: 24739041
[TBL] [Abstract][Full Text] [Related]
2. Androgens induce prostate cancer cell proliferation through mammalian target of rapamycin activation and post-transcriptional increases in cyclin D proteins.
Xu Y; Chen SY; Ross KN; Balk SP
Cancer Res; 2006 Aug; 66(15):7783-92. PubMed ID: 16885382
[TBL] [Abstract][Full Text] [Related]
3. Androgen Receptor-Mediated Growth Suppression of HPr-1AR and PC3-Lenti-AR Prostate Epithelial Cells.
Kim YC; Chen C; Bolton EC
PLoS One; 2015; 10(9):e0138286. PubMed ID: 26372468
[TBL] [Abstract][Full Text] [Related]
4. Androgen receptor functions as a negative transcriptional regulator of DEPTOR, mTOR inhibitor.
Kanno Y; Zhao S; Yamashita N; Yanai K; Nemoto K; Inouye Y
J Toxicol Sci; 2015 Dec; 40(6):753-8. PubMed ID: 26558456
[TBL] [Abstract][Full Text] [Related]
5. Signal transduction pathways in androgen-dependent and -independent prostate cancer cell proliferation.
Ghosh PM; Malik SN; Bedolla RG; Wang Y; Mikhailova M; Prihoda TJ; Troyer DA; Kreisberg JI
Endocr Relat Cancer; 2005 Mar; 12(1):119-34. PubMed ID: 15788644
[TBL] [Abstract][Full Text] [Related]
6. SGK3 is an estrogen-inducible kinase promoting estrogen-mediated survival of breast cancer cells.
Wang Y; Zhou D; Phung S; Masri S; Smith D; Chen S
Mol Endocrinol; 2011 Jan; 25(1):72-82. PubMed ID: 21084382
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of cyclin D1 expression by androgen receptor in breast cancer cells--identification of a novel androgen response element.
Lanzino M; Sisci D; Morelli C; Garofalo C; Catalano S; Casaburi I; Capparelli C; Giordano C; Giordano F; Maggiolini M; Andò S
Nucleic Acids Res; 2010 Sep; 38(16):5351-65. PubMed ID: 20421209
[TBL] [Abstract][Full Text] [Related]
8. Paxillin regulates androgen- and epidermal growth factor-induced MAPK signaling and cell proliferation in prostate cancer cells.
Sen A; O'Malley K; Wang Z; Raj GV; Defranco DB; Hammes SR
J Biol Chem; 2010 Sep; 285(37):28787-95. PubMed ID: 20628053
[TBL] [Abstract][Full Text] [Related]
9. Cyclin D1b variant influences prostate cancer growth through aberrant androgen receptor regulation.
Burd CJ; Petre CE; Morey LM; Wang Y; Revelo MP; Haiman CA; Lu S; Fenoglio-Preiser CM; Li J; Knudsen ES; Wong J; Knudsen KE
Proc Natl Acad Sci U S A; 2006 Feb; 103(7):2190-5. PubMed ID: 16461912
[TBL] [Abstract][Full Text] [Related]
10. The PPARγ ligand ciglitazone regulates androgen receptor activation differently in androgen-dependent versus androgen-independent human prostate cancer cells.
Moss PE; Lyles BE; Stewart LV
Exp Cell Res; 2010 Dec; 316(20):3478-88. PubMed ID: 20932825
[TBL] [Abstract][Full Text] [Related]
11. A cross-talk between the androgen receptor and the epidermal growth factor receptor leads to p38MAPK-dependent activation of mTOR and cyclinD1 expression in prostate and lung cancer cells.
Recchia AG; Musti AM; Lanzino M; Panno ML; Turano E; Zumpano R; Belfiore A; Andò S; Maggiolini M
Int J Biochem Cell Biol; 2009 Mar; 41(3):603-14. PubMed ID: 18692155
[TBL] [Abstract][Full Text] [Related]
12. AIB1 sequestration by androgen receptor inhibits estrogen-dependent cyclin D1 expression in breast cancer cells.
De Amicis F; Chiodo C; Morelli C; Casaburi I; Marsico S; Bruno R; Sisci D; Andò S; Lanzino M
BMC Cancer; 2019 Nov; 19(1):1038. PubMed ID: 31684907
[TBL] [Abstract][Full Text] [Related]
13. Growth inhibition of androgen-responsive prostate cancer cells with brefeldin A targeting cell cycle and androgen receptor.
Rajamahanty S; Alonzo C; Aynehchi S; Choudhury M; Konno S
J Biomed Sci; 2010 Jan; 17(1):5. PubMed ID: 20102617
[TBL] [Abstract][Full Text] [Related]
14. Cyclin D1 repressor domain mediates proliferation and survival in prostate cancer.
Schiewer MJ; Morey LM; Burd CJ; Liu Y; Merry DE; Ho SM; Knudsen KE
Oncogene; 2009 Feb; 28(7):1016-27. PubMed ID: 19079343
[TBL] [Abstract][Full Text] [Related]
15. 6-(3,4-Dihydro-1H-isoquinoline-2-yl)-N-(6-methoxypyridine-2-yl) nicotinamide-26 (DIMN-26) decreases cell proliferation by induction of apoptosis and downregulation of androgen receptor signaling in human prostate cancer cells.
Choi HE; Shin JS; Leem DG; Kim SD; Cho WJ; Lee KT
Chem Biol Interact; 2016 Dec; 260():196-207. PubMed ID: 27720946
[TBL] [Abstract][Full Text] [Related]
16. Changes in androgen receptor nongenotropic signaling correlate with transition of LNCaP cells to androgen independence.
Unni E; Sun S; Nan B; McPhaul MJ; Cheskis B; Mancini MA; Marcelli M
Cancer Res; 2004 Oct; 64(19):7156-68. PubMed ID: 15466214
[TBL] [Abstract][Full Text] [Related]
17. Overexpression of insulin-like growth factor binding protein-5 helps accelerate progression to androgen-independence in the human prostate LNCaP tumor model through activation of phosphatidylinositol 3'-kinase pathway.
Miyake H; Nelson C; Rennie PS; Gleave ME
Endocrinology; 2000 Jun; 141(6):2257-65. PubMed ID: 10830316
[TBL] [Abstract][Full Text] [Related]
18. CA916798 affects growth and metastasis of androgen-dependent prostate cancer cells.
He J; Lan X; Duan HL; Luo H; Zhou XD
Eur Rev Med Pharmacol Sci; 2018 Jul; 22(14):4477-4487. PubMed ID: 30058677
[TBL] [Abstract][Full Text] [Related]
19. Specificity of cyclin D1 for androgen receptor regulation.
Petre-Draviam CE; Cook SL; Burd CJ; Marshall TW; Wetherill YB; Knudsen KE
Cancer Res; 2003 Aug; 63(16):4903-13. PubMed ID: 12941814
[TBL] [Abstract][Full Text] [Related]
20. TGF-beta signaling and androgen receptor status determine apoptotic cross-talk in human prostate cancer cells.
Zhu ML; Partin JV; Bruckheimer EM; Strup SE; Kyprianou N
Prostate; 2008 Feb; 68(3):287-95. PubMed ID: 18163430
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
